Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use* - Wiewrodt, R; Vonk, M; Distler, O; Furst, D; Hachulla, E; Johnson, S; Assassi, S; Meng, L; Quaresma, M; Alves, M; Clerisme-Beaty, E; Wuyts, WA (Pneumologie, 2020)